Goodwill and Other Intangible Assets (Tables)

9 Months Ended

Jan. 23, 2026

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Changes in the Carrying Amount of Goodwill

The following table presents the changes in the carrying amount of goodwill by segment:

(in millions)	Cardiovascular		Neuroscience		Medical Surgical		Diabetes		Total
April 25, 2025	$	8,017	$	11,716	$	19,748	$	2,255	$	41,737
Currency translation and other	20		41		94		—		155
January 23, 2026	$	8,037	$	11,757	$	19,842	$	2,256	$	41,892

Schedule of Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	January 23, 2026				April 25, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,558	$	(10,360)	$	16,550	$	(9,650)
Purchased technology and patents	11,640		(8,151)		11,600		(7,514)
Trademarks and tradenames	422		(292)		421		(283)
Other	357		(120)		355		(101)
Total	$	28,977	$	(18,923)	$	28,925	$	(17,547)
Indefinite-lived:
IPR&D	$	281	$	—	$	289	$	—

Schedule of Gross Carrying Amount of Indefinite-Lived Intangible Assets

The following table presents the gross carrying amount and accumulated amortization of intangible assets:

	January 23, 2026				April 25, 2025
(in millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization
Definite-lived:
Customer-related	$	16,558	$	(10,360)	$	16,550	$	(9,650)
Purchased technology and patents	11,640		(8,151)		11,600		(7,514)
Trademarks and tradenames	422		(292)		421		(283)
Other	357		(120)		355		(101)
Total	$	28,977	$	(18,923)	$	28,925	$	(17,547)
Indefinite-lived:
IPR&D	$	281	$	—	$	289	$	—

Schedule of Estimated Future Aggregate Amortization Expense

Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at January 23, 2026, excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows:

(in millions)	Amortization Expense
Remaining 2026	$	405
2027	1,608
2028	1,557
2029	1,479
2030	1,347
2031	1,268